Datopotamab Deruxtecan, often abbreviated as DATO, represents a important advancement in targeted cancer therapy. This new antibody-drug conjugate joins a monoclonal immunoglobulin specifically directed at HER-2 https://www.targetmol.com/compound/datopotamab